Agenda at a Glance
Market Access Conference Day 2
Day 2: 7th February 2020
08:00 am - Registration
08:50 am - Chairperson’s Welcome and Opening Remarks
Pricing, Reimbursement And Patient Access
09:00 - Market Access for Cell & Gene Therapies in Germany – From RWE to per for performance contracting
Dr. Alexander Natz, Secretary General, European Confederation of Pharmaceutical Entrepreneurs (EUCOPE)
09:35 - Patients access and risk sharing agreements
- New landscape for risk-sharing agreements among manufacturer, payer and patients
- Understand the benefits of a good collaboration between payers and pharma companies to ensure patient access
- What do the decision-makers on drug usage think today about how the industry is responding to the immense challenges it is facing?
Nazanin Mehin, Global Head, Value & Access, Diabetes & Cardiovascular, Sanofi
10:10 - Market access strategies and payer relationships management
- Advantages of market access teams in payer relationship
- Payer evidence requirement in early development
- How effective are the payer strategies in the current climate?
- Best practices to obtain better pricing and reimbursement
- Strategies to improve a better payer relationship
Nicki Catterick, Senior Director, Global Market Access and Pricing, Merck
10:45 am - Morning Break & Networking
11:20 - Designing Winning Clinical Trials for Successful Reimbursement: From Phase II to Phase IIIB and Real-World Evidence Trials
Ryotaro Ishikawa Oka, Global Market Access Director, Novartis
11:55 am - Medicines access challenge – The value of pricing and reimbursement policies
- Innovative approaches required to address the medicine access challenge
- Lessons to be learned from best practices in the field of pricing and reimbursement of medicines
- The value of list prices against the backdrop of external price referencing and managed entry agreements.
- Innovative policy options that needs to be developed, agreed upon and implemented.
Sandro Cesaro-Tadic, Head Global Pricing I8 & Product Pricing Strategies, F. Hoffmann-La Roche
12:30 pm - Networking Lunch
- Advantages of market access teams in payer relationship
- Payer evidence requirement in early development
- Best practices to obtain better pricing and reimbursement
- Strategies to improve a better payer relationship
Collaboration And Looking To The Future
13:30 pm - Value communication (VC) is essential for a successful market access strategy aiming to bring interventions to patients
- Key trends driving increase in value communication
- Target audiences who receive VC information
- Types of VC tools used to achieve market access
- Outsourcing of VC projects
- Areas in need of improvement
- Training needs in VC
Lucy Hoppe, Clinical Effectiveness Manager (Evidence Synthesis), Group Clinical, BUPA
14:05 pm - Global Market Access Trends predicting the future
- Unlocking data from early access
- Effective communications with internal and external stakeholders
- Embracing the digital vision
- Future trends and developments in the healthcare distribution
14:40 - Analysing the potential synergy between RCT/HEOR data and real-world evidence
- Understand the impact of RWE decisions on price and market access
- The shift from RCT to RWE; closing the gap
- RWE strategies
15:15 pm - Tea Break & Networking
15:45 pm - Acquisitions, harmony and collaboration
- Risk sharing agreements: incorporating financial models with performance based/outcome-based models
- How to find the right partner?
- In licensing and out licensing
16:20 pm - Panel Discussion: International collaboration on pricing
- The importance of making MA the core of the company
- Bridge between pre-launch strategy and post-launch
- International Drug Price Indicator Guide WHO
- Increasing collaboration between EU countries
- Frontiers in Health Care
- What will the future bring?
Panellist:
> Sandro Cesaro-Tadic, Head Global Pricing I8 & Product Pricing Strategies, F. Hoffmann-La Roche
17:00 pm - Chairperson's Closing Remarks